03/06/2026
From online forums to the clinic, people have reported that diabetes and weight-loss drugs such as Ozempic and Wegovy can dramatically quell their compulsive behaviors—including cravings for alcohol and ni****ne. The swell of anecdotes has spurred a wave of preliminary trials and one-off studies that have mostly investigated specific substance use disorders individually. But researchers haven’t grasped how broad the effects might be.
Now a large epidemiological study published on Wednesday in the BMJ suggests that glucagonlike peptide 1 (GLP-1) medications—as these drugs are called—reduce the risk of all kinds of substance use disorders, including those involving alcohol, ni****ne, cannabis, opioids and co***ne. Not only did GLP-1 drugs appear to prevent people from developing these addictions, but they also decreased rates of life-threatening events, including drug-related overdoses and deaths.
Seeing reductions across every disorder, “I was like, ‘Is this real?’ because there is nothing like it,” says clinical epidemiologist Ziyad Al-Aly, lead author of the study and chief of research and development at the U.S. Depart of Veterans Affairs St. Louis Health Care System. “This is an obesity and diabetes drug; this is not an addiction drug. So the big surprise was: it was consistently working across all substances.” http://spklr.io/6042ED98j
✍: Lauren J. Young
📸: SimpleImages/Getty Images